Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Cash from Financing Activities: 2016-2025

Historic Cash from Financing Activities for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Sep 2025 value amounting to -$67,000.

  • Rocket Pharmaceuticals' Cash from Financing Activities fell 138.07% to -$67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $183.2 million, marking a year-over-year increase of 5482.84%. This contributed to the annual value of $185.7 million for FY2024, which is 10.87% down from last year.
  • Rocket Pharmaceuticals' Cash from Financing Activities amounted to -$67,000 in Q3 2025, which was down 131.16% from $215,000 recorded in Q2 2025.
  • In the past 5 years, Rocket Pharmaceuticals' Cash from Financing Activities ranged from a high of $189.5 million in Q3 2023 and a low of -$67,000 during Q3 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $787,500 (2023), whereas its average is $39.4 million.
  • Per our database at Business Quant, Rocket Pharmaceuticals' Cash from Financing Activities spiked by 46,664.45% in 2024 and then crashed by 138.07% in 2025.
  • Quarterly analysis of 5 years shows Rocket Pharmaceuticals' Cash from Financing Activities stood at $1.1 million in 2021, then skyrocketed by 9,445.77% to $108.4 million in 2022, then slumped by 99.64% to $391,000 in 2023, then spiked by 46,664.45% to $182.8 million in 2024, then plummeted by 138.07% to -$67,000 in 2025.
  • Its Cash from Financing Activities stands at -$67,000 for Q3 2025, versus $215,000 for Q2 2025 and $182.8 million for Q4 2024.